Researchers announced promising phase-three results for a new dengue vaccine, reporting 84 percent efficacy across all four virus serotypes in a trial involving 20,000 participants.
Regulators are expected to review the data later this year. Public health experts described the results as a potential turning point for a disease that strains hospitals every monsoon season.